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Background
It’s estimated that 10 to 20 million people are infected
with the HTLV-1 virus worldwide. Two principal dis-
eases are associated with this virus: the Adult T-cell
Lymphoma/Leukemia (ATLL), and the HTLV-1 Asso-
ciated Myelopathy/ Tropical Spastic Paraparesis (HAM/
TSP). The last one is a debilitating neurological disease
characterized by a chronic progressive paraparesis, with
autonomic and mild sensorial complains. There are also
incomplete forms of HAM/TSP, sometimes called sub-
clinical or oligosymptomatic. Those mild and moderate
neurological presentations are found in almost one
fourth of the HTLV-1 patients and they include neuro-
genic bladder syndromes, erectile dysfunction, isolated
pyramidal signs and peripheral neuropathy.
Objective
To describe the evolution of neurological disability in
HTLV-1 infected individuals.
Methods
Cohort study with 419 HTLV-1 infected individuals,
divided in three groups according to the main clinical
picture in to:
1. asymptomatic, defined as absence of any neurologi-
cal symptoms or signs;
2. oligosymptomatic, defined by presence of neuro-
genic bladder, erectile dysfunction, minor pyramidal
signs and neuropathy (isolated or in combination);
3. HAM/TSP, as defined by WHO criteria. Those
patients had an annual follow up, including neurological
examination. EDSS was utilized to measure neurological
disability in various domains. Failure was considered as
any worse on EDSS scale or death due to HTLV-1. Cen-
sored was considered as lost of follow up or death due
other causes.
Results
In 419 analyzed patients 67(18,76%) were diagnosed
with HAM/TSP, 96(26,89%) as oligosymptomatics, 194
(54,34%) as asymptomatics. There were 10 deaths on
the cohort and the annual death rate was 0,59/100
patients. In survival analyses there were 71 failures with
an incidence rate of 0,09 individuals/year. Kaplan-Meyer
survival estimate curves with log-rank test showed a sig-
nificant difference between the three curves (p<0.01),
with incidence rates and time at risk of 0,2 and 125 in
H A M / T S P0 , 0 8a n d2 4 2i nn e u r o l o g i c a ls y m p t o m sa n d
0,05 and 445 in asymptomatic. Cox regression showed
that TNF-a higher than 541 pg/ml (ORs 1,95 IC 95%
1,14-3,36), female gender (ORs 2,38 IC 95% 1,34-4,22),
and history of hypotiroidism (ORs 3,64 IC 95% 1,31-
10,08) had a strong association with neurological
decreased function.
Conclusion
Neurological disability in HTLV-1 infected patient
increase with time, and it is worse in groups with symp-
toms or HAM/TSP. Some factors proved to be asso-
ciated with neurological disability and two of them
* Correspondence: davi81@me.com
Immunology, Universidade Federal da Bahia, Salvador, Bahia, Brazil
Costa et al. Retrovirology 2011, 8(Suppl 1):A62
http://www.retrovirology.com/content/8/S1/A62
© 2011 Costa et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.(diabetes and hypotiroidism) is life treating and one
(TNF-a) can be a focus of future pharmacotherapy
interventions studies.
Published: 6 June 2011
doi:10.1186/1742-4690-8-S1-A62
Cite this article as: Costa et al.: Neurological disability in HTLV-1
infected individuals according to the initial clinical presentation: cohort
study. Retrovirology 2011 8(Suppl 1):A62.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Costa et al. Retrovirology 2011, 8(Suppl 1):A62
http://www.retrovirology.com/content/8/S1/A62
Page 2 of 2